

# Frédéric Courbon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3007676/publications.pdf>

Version: 2024-02-01

40  
papers

1,364  
citations

430442

18  
h-index

329751

37  
g-index

42  
all docs

42  
docs citations

42  
times ranked

4427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of <sup>177</sup> Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3529-3537.	3.3	6
2	Gated <sup>18</sup> F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study. <i>Journal of Nuclear Medicine Technology</i> , 2019, 47, 227-232.	0.4	4
3	Incidental Finding of Intrathyroid Metastases of Prostatic Cancer on <sup>18</sup> F-Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2019, 44, e101-e103.	0.7	3
4	Evaluation of 2 diuretic <sup>18</sup> fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 284-291.	0.4	4
5	Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 421-426.	0.6	4
6	Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by <sup>18</sup> F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study). <i>Journal of Nuclear Medicine</i> , 2017, 58, 1045-1053.	2.8	70
7	Clinical outcomes 1 year after empiric <sup>131</sup> I therapy for hyperthyroid disorders. <i>Nuclear Medicine Communications</i> , 2017, 38, 756-763.	0.5	18
8	<sup>18</sup> F-Fluorine- <sup>18</sup> iodo-dihydroxyphenylalanine ( <sup>18</sup> F-DOPA) positive isolated peritoneal carcinomatosis from a MEN1-related medullary thyroid carcinoma. About an atypical metastatic site and utility of <sup>18</sup> F-DOPA. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 81-83.	0.2	1
9	Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or <sup>18</sup> F-FDG PET/CT able to provide an accurate prediction of long-term outcome?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 397-408.	3.3	22
10	Oncocytic Adenoma of Thyroid Incidentally Detected by <sup>18</sup> F-Fluorocholine PET/CT. <i>Journal of Nuclear Medicine Technology</i> , 2015, 43, 133-134.	0.4	18
11	Comparison of an alternative and existing binning methods to reduce the acquisition duration of 4D PET/CT. <i>Medical Physics</i> , 2014, 41, 112503.	1.6	3
12	Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art. <i>Endocrine-Related Cancer</i> , 2014, 21, R105-R120.	1.6	59
13	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. <i>European Journal of Cancer</i> , 2014, 50, 170-177.	1.3	47
14	A new respiratory gating device to improve 4D PET/CT. <i>Medical Physics</i> , 2013, 40, 032501.	1.6	13
15	Interobserver Agreement of Qualitative Analysis and Tumor Delineation of <sup>18</sup> F-Fluoromisonidazole and <sup>3</sup> -Deoxy- <sup>18</sup> F-Fluorothymidine PET Images in Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1543-1550.	2.8	44
16	Breast Imaging: Understanding How Accuracy is Measured When Lesion are the Unit of Analysis. <i>Breast Journal</i> , 2013, 19, 225-226.	0.4	0
17	The retrospective binning method improves the consistency of phase binning in respiratory-gated PET/CT. <i>Physics in Medicine and Biology</i> , 2012, 57, 7829-7841.	1.6	22
18	Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1431-1435.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 129-137.	3.3	14
20	Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. <i>British Journal of Dermatology</i> , 2011, 164, 1235-1240.	1.4	31
21	Evaluation of a Trainer Phantom in the Learning Phase of Sentinel Lymph Node Identification in Breast Cancer. <i>World Journal of Surgery</i> , 2011, 35, 995-1001.	0.8	4
22	Coregistration of Prechemotherapy PET-CT for Planning Pediatric Hodgkin's Disease Radiotherapy Significantly Diminishes Interobserver Variability of Clinical Target Volume Definition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 793-799.	0.4	31
23	Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. <i>Chemistry and Physics of Lipids</i> , 2011, 164, 432-437.	1.5	51
24	Quality controls and delineation protocol of PET/CT gated acquisition in function of the movement amplitude, size of spheres and signal over background ratio. <i>Proceedings of SPIE</i> , 2011, , .	0.8	4
25	Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to in vivo evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5400-5412.	1.4	12
26	Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. <i>British Journal of Cancer</i> , 2010, 103, 61-72.	2.9	12
27	Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 4434-4445.	3.2	27
28	Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. <i>Clinical Endocrinology</i> , 2008, 68, 904-911.	1.2	50
29	Adenoid cystic carcinoma of the lung: Interest of 18FDG PET/CT in the management of an atypical presentation. <i>Lung Cancer</i> , 2008, 59, 133-136.	0.9	18
30	Indium-111 Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 963-970.	0.8	99
31	Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 7086-7092.	3.2	68
32	Preparation and Use of 131I Magic Gel as a Dosimeter for Targeted Radionuclide Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 427-436.	0.7	10
33	Defective Efficacy of Retinoic Acid Treatment in Patients with Metastatic Thyroid Carcinoma. <i>Thyroid</i> , 2006, 16, 1025-1031.	2.4	44
34	V-Q SPECT in Prone Position Is a Suitable Way to Improve Irradiation of Inoperable Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2006, 31, 284-288.	0.7	0
35	Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. <i>European Journal of Endocrinology</i> , 2005, 152, 757-767.	1.9	160
36	The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 271-277.	0.3	100

#	ARTICLE	IF	CITATIONS
37	Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 890-897.	2.2	202
38	Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). <i>British Journal of Cancer</i> , 2003, 89, S84-S91.	2.9	36
39	Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial. <i>British Journal of Cancer</i> , 2001, 85, 1467-1471.	2.9	14
40	A pharmacokinetic interpretation of increasing concentrations of DEHP in haemodialysed patients. <i>Medical Engineering and Physics</i> , 2000, 22, 157-165.	0.8	15